BioMarin's VOXZOGO Shows Promising Results in Hypochondroplasia Trial
Event summary
- BioMarin's Phase 3 CANOPY-HCH-3 study for VOXZOGO in hypochondroplasia met its primary endpoint, showing a 2.33 cm/yr improvement in annualized growth velocity compared to placebo.
- Secondary endpoints, including standing height, height Z-score, and arm span, also showed statistically significant improvements.
- Safety profile consistent with established data in achondroplasia, with no new safety signals observed.
- Supplemental New Drug Application (sNDA) submission to the FDA planned for Q3 2026, followed by submissions to the EMA and other regional health authorities.
The big picture
BioMarin's positive Phase 3 results for VOXZOGO in hypochondroplasia mark a significant milestone in the treatment of rare genetic skeletal disorders. The study's success highlights the potential for VOXZOGO to address unmet medical needs in a condition with no approved therapies. The upcoming regulatory submissions could expand BioMarin's portfolio in the rare disease space, reinforcing its position as a key player in this growing market.
What we're watching
- Regulatory Approval
- The pace at which the FDA and EMA review and approve the sNDA for VOXZOGO in hypochondroplasia will determine the timeline for market entry.
- Market Expansion
- Whether BioMarin can leverage existing infrastructure for achondroplasia to streamline the launch of VOXZOGO for hypochondroplasia.
- Competitive Landscape
- How this approval could position BioMarin as a leader in treating genetic skeletal dysplasias, potentially attracting more investment and partnerships.
Related topics